Newron

View on cash.ch
    • New

    Gähnende Stille aktuell... der Newsflow ist leider etwas abgebrochen.


    Trotzdem bin ich zufrieden auf welchem Level sich der Newron Kurs aktuell halten kann. Nachdem wir bis auf 3.80 Franken eingebrochen sind.


    Habe mich etwas getäuscht, dachte, dass da mehr kommen wird. Glaube aber es ist falsch jetzt darauf zu schliessen, dass etwas schlecht läuft. Nächste Woche ist noch ein Event in Barcelona evtl. kommt vorher noch eine Publikation.


    Gerne möchte ich auch noch auf die Frau Dines eingehen. Viele denken, dass sie ein Gamechanger ist. Ich bin da etwas skeptisch, da der Verwaltungsrat nicht operativ im Unternehmen mitarbeitet. Vielmehr ist er ein Aufsichtsgremium, welcher die Strategie vorgibt und ja in grösseren Entscheidungen/Verhandlungen eingebunden wird. Gemäss Linkedin hat ihre Anstellung bei Jazz Pharma aufgehört, sobald sie in den VR von Newron gewählt wurde.

    • New

    Newron appoints Margarita Chavez as board advisor

    Margarita Chavez, former Managing Director at AbbVie Ventures, to be nominated for election to the Board of Directors at the Ordinary AGM 2024

    Milan, Italy, October 2, 2023 – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous (CNS) system, today announced that Margarita Chavez has been appointed as an advisor to the Board of Directors of Newron, bringing significant pharmaceutical business development (BD) and dealmaking expertise. It is intended that Margarita Chavez will be nominated for election to the Board of Directors at Newron’s next Ordinary Annual General Meeting (AGM) of Shareholders in spring 2024.


    Margarita Chavez brings to Newron over 20 years of dealmaking expertise and leadership in the pharmaceutical industry. Most recently, she was Managing Director of AbbVie Ventures and served as a board member of several U.S. - based biotech companies. As a Director in Abbott’s Global Pharmaceutical Licensing & Acquisitions Division, she was involved in the successful in-licensing of Elagolix and the acquisitions of Solvay, ImmuVen and the Lupron franchise. Before joining Abbott, Ms. Chavez practiced as a corporate and securities lawyer in the Silicon Valley, advising tech and biotech companies on strategic transactions including IPOs and mergers and acquisitions. She received her bachelor’s degree from Santa Clara University and her juris doctor from Santa Clara University School of Law (both California).


    Ulrich Köstlin, Chairman of the Board of Directors of Newron, commented: “We are delighted that Margarita will be supporting us with her vast international dealmaking expertise as a Board advisor and we are convinced that she will as of the AGM 2024 significantly strengthen our Board of Directors as new member. Margarita is a seasoned venture investor and board member with a demonstrated track record of leadership in our industry. Her wide-ranging skills and career across the pharmaceutical industry, including her CNS dealmaking expertise, will be invaluable for Newron. We warmly welcome Margarita to our team.”